Fundraising Fox
Martin Heidecker
InvestorChief Investment Officer at AMR Action Fund · Board director at Rgenta Therapeutics · Board director at Elion Therapeutics · Board director at Abexxa Biologics
Cambridge, Massachusetts, United States
Find your path to Martin
124 people in our graph can introduce you to Martin.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Hemanta Baruah to introduce you to Martin
You →Hemanta · together at Abexxa Biologics (2016–2018) →Martin
Ask Jamie Chen to introduce you to Martin
You →Jamie · together at Libra Therapeutics →Martin
Ask Sam Okafor to introduce you to Martin
You →Sam · 2 people · together at ArmaGen Technologies →Martin
Sign up to find every way you can get introduced to Martin
- Your email: the people you already email who know Martin
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Martin
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Joined the fund in August 2021 with international experience in venture capital, drug development, and pharmaceutical marketing. He was previously Managing Director USA of Boehringer Ingelheim Venture Fund and began his investing career at Bayern Kapital in Germany.
Contact· published on Martin's own website
Board director at Rgenta Therapeutics
Intro paths
In turn, Martin can intro founders to Rgenta Therapeutics's investors below.
Rgenta Therapeutics's investors · 8
Co-founders at Rgenta Therapeutics
Board director at Elion Therapeutics
Intro paths
In turn, Martin can intro founders to Elion Therapeutics's investors below.
Elion Therapeutics's investors · 3
Board director at Abexxa Biologics
Intro paths
In turn, Martin can intro founders to Abexxa Biologics's investors below.
Abexxa Biologics's investors · 1
Co-founders at Abexxa Biologics
Experience
- AMR Action FundChief Investment Officercurrent2021 — presentBoston, Massachusetts, United States
- AMR Action FundMember Board of Directors AMR action2020 — 2021
- MassBioBoard Member MassBio Biotechnologycurrent2020 — presentCambridge, Massachusetts, United States
- Libra TherapeuticsMember Board of Directors Libra Therapeutics Inc.2020 — 2021San Diego, California, United States
- Tiga Therapeutics Inc.Member Board of Directors Tiga Tx Inc.2020 — 2021Cambridge, Massachusetts, United States
- Rgenta Therapeutics Inc.Member Board of Directors Rgenta Therapeutics Inc.2020 — 2021Cambridge, Massachusetts, United States
- Abexxa Biologics, Inc.Member Board of Directors Abexxa Biologics Inc.2016 — 2021Arlington, Texas, United States
- Sentien Biotechnologies, Inc.Member Board of Directors2015 — 2021Medford, MA
- Boehringer Ingelheim Venture Fund USA Inc.Managing Director BIVF USA Inc.2013 — 2021Cambridge, Massachusetts
- ArmaGen TechnologiesMember Board of Directors2012 — 2020Calabasis, California
- 121 Bio LLCMember Board of Directors2014 — 2016Cambridge, MA
- AMP TherapeuticsMember Board of Directors2012 — 2015Leipzig Area, Germany
- Boehringer IngelheimDirector, Investment Manager2010 — 2013Ingelheim, Germany
- Boehringer IngelheimTeam Leader Business Analysis CNS&Oncology2009 — 2010Ingelheim, Germany
- Boehringer IngelheimSenior International Manager Business Analysis2007 — 2009
- Solvay Pharmaceuticals GmbH - Solvay HQSenior Global Business Analyst2004 — 2007
- Solvay PharmaceuticalsGlobal Business Analyst2004 — 2007
- DEWB, BayernkapitalInvestment Manager2001 — 2004
Skills & more
+12 more
Drug DevelopmentTechnology TransferGlobal MarketingSales EffectivenessCompetitive IntelligenceCardiologyClinical TrialsCommercializationPharmaceutical IndustryMedical DevicesVaccinesDiabetesFrom Martin's professional profile.
Deals · 4
Vedanta BiosciencesBoard seat
via AMR Action Fund · filed Aug 2024 · $118.5M raise
Adaptive Phage TherapeuticsBoard seat
via AMR Action Fund · filed Jun 2023 · $30M raise
Rgenta TherapeuticsBoard seat
via AMR Action Fund · filed Mar 2021 · $38M raise
Abexxa BiologicsBoard seat
via AMR Action Fund · filed Sep 2016 · $1.7M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Elion TherapeuticsVENATORX PHARMACEUTICALS INC
Investor
ArmaGen TechnologiesBioVersysLibra TherapeuticsSentien BiotechnologiesSentieon Inc.VENATORX PHARMACEUTICALS INC
Sources: SEC Form D filings · curated public sources.
Colleagues at AMR Action Fund
Frequently asked questions
- Who is Martin Heidecker?
- Joined the fund in August 2021 with international experience in venture capital, drug development, and pharmaceutical marketing. He was previously Managing Director USA of Boehringer Ingelheim Venture Fund and began his investing career at Bayern Kapital in Germany.
- Where does Martin Heidecker work?
- Martin Heidecker is Chief Investment Officer at AMR Action Fund and Board director at Rgenta Therapeutics and Board director at Elion Therapeutics and Board director at Abexxa Biologics.
- What boards does Martin Heidecker sit on?
- Martin Heidecker holds tracked board seats at Abexxa Biologics, Adaptive Phage Therapeutics, Elion Therapeutics, Rgenta Therapeutics, Vedanta Biosciences, VENATORX PHARMACEUTICALS INC.
- What companies has Martin Heidecker invested in?
- Investments tracked here include Adaptive Phage Therapeutics, ArmaGen Technologies, BioVersys, Libra Therapeutics, Rgenta Therapeutics, Sentien Biotechnologies, Sentieon Inc., Vedanta Biosciences, VENATORX PHARMACEUTICALS INC.
- Where did Martin Heidecker go to school?
- Martin Heidecker studied at The Julius Maximilians University of Würzburg (Doctor of Philosophy (PhD), Biology).
Same school
Also attended The Julius Maximilians University of Würzburg38
+ 32 more
Shared employers
Also worked at AMR Action Fund10
+ 4 more
Also worked at MassBio17
+ 11 more
